"ACL tears, genetic markers, maternal mortality —
these are not soft issues. They are quantitatively investable."
The market has systematically underpriced woman-centric health. I deploy capital where that gap is widest — 2ドルB+ AUM in institutional finance, now 10+ early-stage co-investments across immuno-oncology, precision oncology, and genomic solutions particular to Black women. I make that case in the language capital markets understand.
This focus was shaped by proximity: early detection of ovarian cancer, parental cancer, an MPH investigating maternal mortality and genetic predispositions. That lived expertise sharpens every investment thesis I write and every tool I build.
I built Lacuna — an M&A intelligence platform that maps acquirer-target networks, scores deal probability, and surfaces pricing anomalies across healthcare dealflow.
Quantitative Finance · Applied AI · M&A Intelligence · Oncology & Genomics · Women's Sport
Women's sport: a profoundly undervalued lens for health outcomes — and a compelling investment thesis in its own right.
